| Id: | acc1518 |
| Group: | 2sens |
| Protein: | FKHRL1 |
| Gene Symbol: | FOXO3 |
| Protein Id: | O43524 |
| Protein Name: | FOXO3_HUMAN |
| PTM: | phosphorylation |
| Site: | Ser321 |
| Site Sequence: | RTNSNASTVSGRLSPIMASTE |
| Disease Category: | Cancer |
| Disease: | Hepatocellular Carcinoma |
| Disease Subtype: | |
| Disease Cellline: | Hep3B |
| Disease Info: | |
| Drug: | SYUNZ-16 |
| Drug Info: | - |
| Effect: | modulate |
| Effect Info: | SYUNZ-16 induces apoptosis of human lung adenocarcinoma cells GLC-82 and liver cancer cells Hep3B and inhibits tumor growth by suppressing the activity of PKB/AKT kinase (protein phosphorylation) and blocking the AKT/FOXO signaling pathway. |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 19904742 |
| Sentence Index: | 19904742_7-8 |
| Sentence: | "Additionally, SYUNZ-16 partially attenuated the phosphorylation levels of FKHR and FKHRL1 in a dose-dependent and time-dependent fashion, and led to an increase in the nuclear accumulation of exogenous FKHR, and upregulated the mRNA expression of Bim and TRADD in cancer cells. Further study showed that constitutively activated AKT1 transfection could reduce apoptosis induction mediated by SYUNZ-16." |
Sequence & Structure:
MAEAPASPAPLSPLEVELDPEFEPQSRPRSCTWPLQRPELQASPAKPSGETAADSMIPEEEDDEDDEDGGGRAGSAMAIGGGGGSGTLGSGLLLEDSARVLAPGGQDPGSGPATAAGGLSGGTQALLQPQQPLPPPQPGAAGGSGQPRKCSSRRNAWGNLSYADLITRAIESSPDKRLTLSQIYEWMVRCVPYFKDKGDSNSSAGWKNSIRHNLSLHSRFMRVQNEGTGKSSWWIINPDGGKSGKAPRRRAVSMDNSNKYTKSRGRAAKKKAALQTAPESADDSPSQLSKWPGSPTSRSSDELDAWTDFRSRTNSNASTVSGRLSPIMASTELDEVQDDDAPLSPMLYSSSASLSPSVSKPCTVELPRLTDMAGTMNLNDGLTENLMDDLLDNITLPPSQPSPTGGLMQRSSSFPYTTKGSGLGSPTSSFNSTVFGPSSLNSLRQSPMQTIQENKPATFSSMSHYGNQTLQDLLTSDSLSHSDVMMTQSDPLMSQASTAVSAQNSRRNVMLRNDPMMSFAAQPNQGSLVNQNLLHHQHQTQGALGGSRALSNSVSNMGLSESSSLGSAKHQQQSPVSQSMQTLSDSLSGSSLYSTSANLPVMGHEKFPSDLDLDMFNGSLECDMESIIRSELMDADGLDFNFDSLISTQNVVGLNVGNFTGAKQASSQSWVPG
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTAC| FOXO3-Ser321 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | |
| HGSC | |
| ccRCC | |
| GBM | |
| HNSC | |
| LUAD | |
| LUSC | |
| non_ccRCC | |
| PDAC | |
| UCEC | |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| K | 270 | D | Hepatic ischemic/reperfusion injury | Acetylation | 33298860 |
| K | 289 | D | Hepatic ischemic/reperfusion injury | Acetylation | 33298860 |
| S | 574 | P | Hepatitis C virus infection | Phosphorylation | 23857333 |
| - | - | U | Nasopharyngeal carcinoma | Acetylation | 31727006 |
| K | 242 | U | B-cell acute lymphoblastic leukemia | Acetylation | 26376801 |
| K | 245 | U | B-cell acute lymphoblastic leukemia | Acetylation | 26376801 |
| S | 7 | U | B-cell acute lymphoblastic leukemia | Phosphorylation | 26376801 |
| S | 253 | U | Breast cancer | Phosphorylation | 36797347 |
| S | 253 | U | Prostate cancer/carcinoma/adenocarcinoma | Phosphorylation | 24067903 |
| T | 32 | U | Breast cancer | Phosphorylation | 36797347 |
| T | 32 | U | Non-small cell lung cancer | Phosphorylation | 35459265 |
| - | - | U | Renal cell carcinoma | Phosphorylation | 36923928 |
| - | - | U | X-linked myotubular myopathy | Phosphorylation | 23695157 |
| - | - | U | Paget's disease | Phosphorylation | 23262029 |
| - | - | U | Acute myeloid leukemia/acute myelogenous leukemia | Phosphorylation | 20215543 |
| - | - | U | Asthma | Ubiquitination | 33837090 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
